Using blood inflammation markers (CRP, albumin, CAR, mGPS) to predict outcomes in diffuse large B‑cell lymphoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a prospective observational cohort of adults with treatment‑naïve diffuse large B‑cell lymphoma receiving standard R‑CHOP chemotherapy at Ain Shams University. Investigators will measure CRP, serum albumin, the CRP‑to‑albumin ratio (CAR), and the modified Glasgow Prognostic Score (mGPS) at baseline and after three cycles of treatment. Treatment response will be classified by Lugano criteria and toxicity graded by CTCAE v5.0, with comparisons made between marker levels and outcomes including objective response rate and treatment‑related toxicity. The study also examines how these markers relate to clinical features such as stage and performance status to inform prognostic models.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age ≥ 18 years and ≤ 65 years
* Pathologically confirmed, treatment-naïve diffuse large B-cell lymphoma (DLBCL)
* Any stage of disease (nodal or extra-nodal), with or without B symptoms
* Scheduled to receive standard systemic treatment (R-CHOP)
* ECOG performance status 0-2
* Baseline normal:
* Complete blood count (CBC)
* Hepatitis viral markers
* Liver and renal function tests
* Urine analysis
* Echocardiogram
* Additional investigations to exclude current infection if clinically indicated

Exclusion Criteria:

* History of other concurrent or previous malignancies
* Relapsed or refractory DLBCL
* Uncontrolled comorbid conditions that may interfere with study participation, including:
* Diabetes mellitus
* Autoimmune diseases
* Active infections
* Chronic inflammatory diseases
* Cardiac dysfunction
* Liver cell failure
* Pregnant females

Where it's running

• Clinical Oncology and Nuclear Medicine Department, Faculty of Medicine, Ain Shams University
  Cairo, Cairo Governorate, Egypt Recruiting

Study contacts

• Principal investigator: Mahmoud M Ellithy, MD — Faculty of Medicine, Ain Shams University
• Study coordinator: Alaa M Elsayed, MSc
• Email: alaa.abdou@med.asu.edu.eg
• Phone: +201112490913

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Orelabrutinib plus Pola-R-CHP as first-line treatment for intermediate- to high-risk DLBCL

  This trial tests whether adding orelabrutinib to the Pola-R-CHP regimen can improve outcomes for adults with intermediate- to high-risk newly diagnosed DLBCL.

  Recruiting at 2 sites The First Affiliated Hospital of Xiamen University · Xiamen, Fujian and 1 other locations · NCT07778212

• Hypofractionated Radiotherapy plus GM-CSF, Pomalidomide and Glofitamab for Newly Diagnosed PCNS-DLBCL

  This study tests a combination therapy—hypofractionated radiotherapy with GM-CSF, pomalidomide, and glofitamab—for adults newly diagnosed with primary CNS DLBCL to see if it helps control the disease.

  Recruiting Phase 2 The First Affiliated Hospital of Xiamen University · Xiamen, Fujian · NCT07749365

• Modified DHAP vs Standard DHAP in relapsed/refractory DLBCL

  This phase 3 trial tests whether a split, lower-dose version of DHAP is as effective as the standard regimen for adults with relapsed or refractory DLBCL and tries to reduce toxicities.

  Recruiting Phase 3 King Edward Medical University · Lahore, Punjab Province · NCT07739654

• Orelabrutinib plus standard immunochemotherapy with or without auto-HSCT for newly diagnosed DLBCL

  This study tests whether adding orelabrutinib to standard chemotherapy, with or without autologous stem cell transplantation, helps newly diagnosed DLBCL patients.

  Recruiting Phase 2 The Affiliated Hospital of Xuzhou Medical University · Xuzhou, Jiangsu · NCT07680933

• SCTB35 with Gemcitabine and Oxaliplatin in relapsed or refractory DLBCL

  This trial tests whether SCTB35 added to gemcitabine and oxaliplatin helps people with relapsed or refractory diffuse large B-cell lymphoma stay disease-free longer compared with rituximab plus gemcitabine and oxaliplatin.

  Recruiting Phase 3 Sinocelltech Ltd. · Beijing · NCT07570823

• CT1182 CAR‑T infusion for adults with relapsed or refractory B‑cell non‑Hodgkin lymphoma

  This trial tests whether a CT1182 CAR‑T cell infusion is safe and can help adults 18–75 with relapsed or refractory B‑cell non‑Hodgkin lymphoma.

  Recruiting Early Phase 1 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, Hubei · NCT07548697

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.